Results 121 to 130 of about 1,255,934 (217)

High-mobility group box 1 increases platelet surface P2Y12 and platelet activation in sickle cell disease

JCI Insight
Thrombosis and inflammation are intimately linked and synergistically contribute to the pathogenesis of numerous thromboinflammatory diseases, including sickle cell disease (SCD).
Deirdre Nolfi-Donegan, Gowtham K. Annarapu, Claudette St. Croix, Michael Calderon, Cheryl A. Hillery, Sruti Shiva   +5 more
doaj   +1 more source

Off-Target Effects of P2Y12 Receptor Inhibitors: Focus on Early Myocardial Fibrosis Modulation. [PDF]

Int J Mol Sci, 2023
Lofrumento F, Irrera N, Licordari R, Perfetti S, Nasso E, Liotta P, Isgrò G, Garcia-Ruiz V, Squadrito F, Carerj S, Di Bella G, Micari A, Costa F.   +12 more
europepmc   +1 more source

Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: Systematic review and meta-analysis

, 2019
Background: Early administration of P2Y12-receptor inhibitors is recommended in all patients with acute coronary syndrome undergoing invasive management, with the aim to achieve the fastest and most effective platelet inhibition.
Campo G., Parodi G., Bilotta F., Tonet E., Vitali F., Serenelli M., Pavasini R.   +6 more
core   +1 more source

Risk of major adverse cardiovascular events in CYP2C19 LoF genotype guided clopidogrel against alternative antiplatelets for CAD patients undergoing PCI: Meta‐analysis

Clinical and Translational Science
Selection of rational antagonists of P2Y12 receptor for CAD patients who inherit CYP2C19 LoF alleles remains still conflicting. This study compared the clinical outcomes in CAD patients inheriting CYP2C19 LoF alleles undergoing PCI and treated with ...
Mohitosh Biswas, Murshadul Alam Murad, Maliheh Ershadian, Most Sumaiya Khatun Kali, Chonlaphat Sukasem   +4 more
doaj   +1 more source

The role of the purinergic receptor P2Y12 in Alzheimer's disease

Alzheimer’s disease (AD), the most common cause of dementia, shows a significant rise in prevalence due to increased global life expectancy and represents a major public health, social, and economic burden. Microglia, the resident immune cells of the CNS,
Maruccia, Riccardo
core   +1 more source

Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists. [PDF]

Biomolecules, 2023
Hsin CH, Dingemanse J, Henrich A, Bernaud C, Gehin M, Krause A.   +5 more
europepmc   +1 more source

Pharmacogenetics of P2Y₁₂ receptor inhibitors. [PDF]

Pharmacotherapy, 2023
Thomas CD, Williams AK, Lee CR, Cavallari LH.   +3 more
europepmc   +1 more source

Opioids and oral P2Y12 receptor inhibitors: A drug-drug interaction. [PDF]

Cardiol J, 2022
Kubica J.
europepmc   +1 more source

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel. [PDF]

Clin Transl Sci, 2022
Schilling U, Hsin CH, Delahaye S, Krause A, Wuelfrath H, Halabi A, Dingemanse J.   +6 more
europepmc   +1 more source

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease. [PDF]

BMC Cardiovasc Disord, 2022
Zhang YJ, Li DJ, Li ZY, Hu XL, Li H, Ma QL, Chen XP.   +6 more
europepmc   +1 more source